Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment

Insight Molecular Diagnostics Inc.

10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.
GraftAssure RUO launch expected Q2 2024 at select US/EU transplant centers, broader rollout H2 2024.
Bio-Rad gets exclusive global distribution rights outside US/Germany; option for IVD rights upon FDA clearance with second equity investment.
Transplant monitoring market estimated over $1B with 157K annual transplants and 9.1% growth.
Bio-Rad makes initial equity investment in Oncocyte; specific amount not disclosed.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).

Action: entry
Agreement: collaboration
Counterparty: Bio-Rad Laboratories, Inc.
Effective: 2024-04-05

Exact text from the filing

On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-014355

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.